Treatment with low-dose oral etoposide in patients with myelodysplastic syndromes

Leukemia Research

Volumn 22, Issue 1, 1998, Pages 7-12

  Doll, Donald C ^a   Kasper, Lawrence M ^b   Taetle, Raymond ^b   List, Alan F ^b  

^a University of Missouri   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

Myelodysplastic syndrome; Oral etoposide

Indexed keywords

ANTINEOPLASTIC AGENT; ETOPOSIDE; HYDROXYUREA;

ADULT; AGED; ANOREXIA; ARTICLE; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; FEVER; HUMAN; INFECTION; MALE; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REMISSION; SEPSIS; VOMITING;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ETOPOSIDE; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; TREATMENT OUTCOME;

EID: 0031981661     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(97)00149-5     Document Type: Article

References (14)

1. 1. List, A. F., Garewal, H. S. and Sandberg, A. A., The myelodysplastic syndromes: biology and implications for management. J. Clin. Oncol., 1990, 8, 1424.
2. 2. Cheson, B. D., The myelodysplastic syndromes: current approaches to therapy. Ann. Intern. Med., 1990, 112, 932.
3. 3. Rappa, G., Lorico, A. and Sartorelli, A. C., Induction of the differentiation of WEHI - 3BD + monomyelocytic leukemia cells by inhibitors of topoisomerase II. Cancer Res., 1990, 50, 6723.
4. 4. Walker, P. R., Smith, C. Youdale, T., Leblanc, J., Whitfield, J. F. and Sikorska, M., Topoisomerase II-reactive chemotherapeutic drugs induce apoptosis in thymocytes. Cancer Res., 1991, 51, 1078.
5. 5. Oscier, D. G., Worsley, A., Hamblin, T. J. and Mufti, G. J., Treatment of chronic myelomonocytic leukemia with low dose etoposide. Br. J. Haematol., 1989, 72, 468.
6. 6. Sato, K., Ushijama, T., Ohbayashi, Y. and Urabe, A., Low-dose etoposide in the treatment of chronic myelomonocytic leukemia. Rinsho Ketsueki, 1990, 4, 521.
7. 7. Bennett, J. M., Catovsky, D., Daniel, M. T., Flandrin, G., Galton, D. A. G., Gralnick, H. R. and Sultan, C., Proposals for the classification of the myelodysplastic syndromes. Br. J. Haematol., 1982, 51, 189
8. 8. Doll, D. C., Sun, P. C. and List, A. F., Complete hematologic remission with oral etoposide in a patient with chronic myelomonocytic leukemia and profound dyserythropoiesis. Leukemia Res., 1994, 18, 381.
9. 9. Ogata, K., Yamada, T., Ito, T., Gomi, S., Tanabe, Y., Ohki, I., Dan, K. and Nomura, T., Low-dose etoposide: a potential therapy for myelodysplastic syndromes. Br. J. Haematol., 1992, 82, 354.
10. 10. Makaya, K., Chou, S., Kaneko, M. and Makamura, Y., Topoisomerase inhibitors have potent differentiation-inducing activity for human and mouse myeloid leukemia cells. Jpn. J. Cancer Res., 1991, 82, 184.
11. 11. Rius, C., Zorrilla, A. R., Cabanas, C., Mata, F., Bernakeu, C. and Aller, P., Differentiation of human promonocytic leukemia U-937 cells with DNA topoisomerase II inhibitors: induction of vimentin gene expression. Mol. Pharmacol., 1991, 39, 442.
12. 12. Group Francais des Myelodysplasias and European CMML Group, Wattel, E., Fuerci, A., Hecquet, B., Economopoulos, T., Cobblestone, A., Mahe, B., Couteaux, M. E., Resegotti, L., Voglova, V., Foussard, C., Pegourie, B., Michaux, J. L., Deconinck, K., Stoppa, A. M., Mugti, G., Oscier, D. and Fenaux, P., A randomized trial of hydroxyurea versus VP 16 in adult chronic myelomonocytic leukemia. Blood, 1996, 88, 2481.
13. 13. Gill Super, H. J., McCabe, N. R., Thirman, M. J., Larson, R. A., LeBeau, M. M., Pedersen-Bjergaard, J., Phillip, P., Diaz, M. O. and Rowley, J. D., Rearrangements of the MLL gene in therapy related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II. Blood, 1993, 82, 3705.
14. 14. Hande, K. R., Krozely, M. G., Greco, A., Hainsworth, J. D. and Johnson, D. H., Bioavailability of low-dose oral etoposide. J. Clin. Oncol., 1993, 11, 374